BR112021022889A8 - Derivados heterocíclicos fundidos, seus usos, composição farmacêutica e produto compreendendo os mesmos e método para a preparação dos mesmos - Google Patents
Derivados heterocíclicos fundidos, seus usos, composição farmacêutica e produto compreendendo os mesmos e método para a preparação dos mesmosInfo
- Publication number
- BR112021022889A8 BR112021022889A8 BR112021022889A BR112021022889A BR112021022889A8 BR 112021022889 A8 BR112021022889 A8 BR 112021022889A8 BR 112021022889 A BR112021022889 A BR 112021022889A BR 112021022889 A BR112021022889 A BR 112021022889A BR 112021022889 A8 BR112021022889 A8 BR 112021022889A8
- Authority
- BR
- Brazil
- Prior art keywords
- same
- preparing
- fused heterocyclic
- product
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962853533P | 2019-05-28 | 2019-05-28 | |
| EP19176933 | 2019-05-28 | ||
| CN2020085720 | 2020-04-20 | ||
| PCT/US2020/034643 WO2020243135A1 (en) | 2019-05-28 | 2020-05-27 | Fused heterocyclic derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112021022889A2 BR112021022889A2 (pt) | 2022-01-04 |
| BR112021022889A8 true BR112021022889A8 (pt) | 2024-03-05 |
Family
ID=71741889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021022889A BR112021022889A8 (pt) | 2019-05-28 | 2020-05-27 | Derivados heterocíclicos fundidos, seus usos, composição farmacêutica e produto compreendendo os mesmos e método para a preparação dos mesmos |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP3976617B1 (https=) |
| JP (1) | JP2022535734A (https=) |
| KR (1) | KR20220012913A (https=) |
| CN (1) | CN113906028A (https=) |
| AU (1) | AU2020285718A1 (https=) |
| BR (1) | BR112021022889A8 (https=) |
| CA (1) | CA3138168A1 (https=) |
| CL (1) | CL2021003155A1 (https=) |
| CO (1) | CO2021016433A2 (https=) |
| CR (1) | CR20210666A (https=) |
| DO (1) | DOP2021000230A (https=) |
| IL (1) | IL288322A (https=) |
| JO (1) | JOP20210313A1 (https=) |
| MA (1) | MA56043A (https=) |
| MX (1) | MX2021014575A (https=) |
| PE (1) | PE20220767A1 (https=) |
| PH (1) | PH12021552974A1 (https=) |
| SG (1) | SG11202113167QA (https=) |
| WO (1) | WO2020243135A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022116999A1 (en) * | 2020-12-02 | 2022-06-09 | Janssen Sciences Ireland Unlimited Company | Fused heterocyclic derivatives and their use in the treatment of hbv infection |
| AR124222A1 (es) * | 2020-12-02 | 2023-03-01 | Janssen Sciences Ireland Unlimited Co | Derivados heterocíclicos condensados |
| WO2022116998A1 (en) * | 2020-12-02 | 2022-06-09 | Janssen Sciences Ireland Unlimited Company | Fused heterocyclic derivatives as hbv inhibitors |
| US20240279227A1 (en) * | 2021-06-02 | 2024-08-22 | Janssen Sciences Ireland Unlimited Company | Fused heterocyclic derivatives |
| AR126049A1 (es) | 2021-06-02 | 2023-09-06 | Janssen Sciences Ireland Unlimited Co | Derivados heterocíclicos condensados |
| WO2024114709A1 (en) * | 2022-12-01 | 2024-06-06 | Janssen Sciences Ireland Unlimited Company | A crystal form of a fused heterocycle derivative compound |
| WO2024140851A1 (zh) * | 2022-12-28 | 2024-07-04 | 上海维申医药有限公司 | 一类Toll样受体抑制剂及其制备和应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2993174A1 (en) * | 2014-09-08 | 2016-03-09 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH | Pyrazolopyridine derivatives and their use in therapy |
| WO2016109684A2 (en) * | 2014-12-30 | 2016-07-07 | Novira Therapeutics, Inc. | Derivatives and methods of treating hepatitis b infections |
| AU2017290755B2 (en) * | 2016-06-29 | 2021-07-01 | Novira Therapeutics, Inc. | Diazepinone derivatives and their use in the treatment of hepatitis B infections |
| EP3478692B1 (en) * | 2016-06-29 | 2020-06-17 | Novira Therapeutics Inc. | Oxadiazepinone derivatives and their use in the treatment of hepatitis b infections |
| BR112021021564A2 (pt) * | 2019-04-30 | 2022-01-04 | Aicuris Gmbh & Co Kg | Indol-2-carboxamidas inovadoras ativas contra o vírus da hepatite b (hbv) |
-
2020
- 2020-05-27 WO PCT/US2020/034643 patent/WO2020243135A1/en not_active Ceased
- 2020-05-27 CR CR20210666A patent/CR20210666A/es unknown
- 2020-05-27 JP JP2021570274A patent/JP2022535734A/ja active Pending
- 2020-05-27 EP EP20744199.9A patent/EP3976617B1/en active Active
- 2020-05-27 CN CN202080039617.8A patent/CN113906028A/zh active Pending
- 2020-05-27 SG SG11202113167QA patent/SG11202113167QA/en unknown
- 2020-05-27 AU AU2020285718A patent/AU2020285718A1/en not_active Abandoned
- 2020-05-27 PE PE2021001959A patent/PE20220767A1/es unknown
- 2020-05-27 MX MX2021014575A patent/MX2021014575A/es unknown
- 2020-05-27 PH PH1/2021/552974A patent/PH12021552974A1/en unknown
- 2020-05-27 MA MA056043A patent/MA56043A/fr unknown
- 2020-05-27 BR BR112021022889A patent/BR112021022889A8/pt unknown
- 2020-05-27 KR KR1020217042210A patent/KR20220012913A/ko not_active Withdrawn
- 2020-05-27 CA CA3138168A patent/CA3138168A1/en active Pending
-
2021
- 2021-11-05 DO DO2021000230A patent/DOP2021000230A/es unknown
- 2021-11-23 IL IL288322A patent/IL288322A/en unknown
- 2021-11-25 JO JOP/2021/0313A patent/JOP20210313A1/ar unknown
- 2021-11-26 CL CL2021003155A patent/CL2021003155A1/es unknown
- 2021-12-01 CO CONC2021/0016433A patent/CO2021016433A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DOP2021000230A (es) | 2022-05-31 |
| BR112021022889A2 (pt) | 2022-01-04 |
| MA56043A (fr) | 2022-04-06 |
| CL2021003155A1 (es) | 2022-07-22 |
| WO2020243135A1 (en) | 2020-12-03 |
| SG11202113167QA (en) | 2021-12-30 |
| CA3138168A1 (en) | 2020-12-03 |
| PH12021552974A1 (en) | 2022-07-11 |
| IL288322A (en) | 2022-01-01 |
| JP2022535734A (ja) | 2022-08-10 |
| CN113906028A (zh) | 2022-01-07 |
| KR20220012913A (ko) | 2022-02-04 |
| JOP20210313A1 (ar) | 2021-11-25 |
| PE20220767A1 (es) | 2022-05-16 |
| MX2021014575A (es) | 2022-05-24 |
| CR20210666A (es) | 2022-03-11 |
| CO2021016433A2 (es) | 2021-12-10 |
| EP3976617B1 (en) | 2025-04-23 |
| EP3976617A1 (en) | 2022-04-06 |
| AU2020285718A1 (en) | 2022-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021022889A8 (pt) | Derivados heterocíclicos fundidos, seus usos, composição farmacêutica e produto compreendendo os mesmos e método para a preparação dos mesmos | |
| BR112019007039A2 (pt) | pirrolidinas substituídas e seus métodos de uso no tratamento de fibrose cística | |
| BR112019003557A2 (pt) | derivados de oxopicolinamida, método de preparação dos mesmos e uso farmacêutico dos mesmos | |
| BR112015023948A2 (pt) | composto de fórmula (i), composição farmacêutica, método para o tratamento e/ou prevenção de uma doença proliferativa e para a inibição ou a diferenciação do crescimento de uma célula tronco do câncer | |
| BR112021021508A2 (pt) | Derivados de 3-amino-4h-benzo[e][1,2,4]tiadiazina 1,1-dióxido como inibidores de mrgx2 | |
| BR112015016793A2 (pt) | compostos de tiazolacarboxamidas e piridinacarbo-xamida úteis como inibidores de quinase pim | |
| JOP20180026A1 (ar) | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك | |
| BR112018008397A2 (pt) | derivados de di-hidroimidazopirazinona úteis no tratamento do câncer | |
| BR112017017500A2 (pt) | derivado de quinolina para uso no tratamento e prevenção de infecções virais | |
| EA202192512A1 (ru) | Пиримидоновые производные с конденсированными кольцами для применения в лечении инфекции, вызванной hbv, или заболеваний, вызванных hbv | |
| BR112017026191A2 (pt) | compostos tricíclicos e seu uso como inibidores de fosfodiesterase | |
| BR112015019412A8 (pt) | inibidores de bace1, seus usos, e composição farmacêutica | |
| BR112017001160A2 (pt) | [1,2,4]triazol[4,3-b]piridazinas para uso no tratamento de doenças proliferativas | |
| CL2018002095A1 (es) | Un derivado de piridina representado por las formulas i a iii y una sal farmacéuticamente aceptable del mismo; procedimiento de preparación del derivado de piridina o la sal farmacéuticamente aceptable del mismo; composición farmacéutica y su uso para preparar un medicamento útil para la prevención o tratamiento de una enfermedad de crecimiento celular anómalo producida por una mutación ras. | |
| BR112021023114A2 (pt) | Derivados heterocíclicos fundidos, seus usos, composição farmacêutica e produto dos mesmos e processo para a preparação dos derivados heterocíclicos fundidos e composição farmacêutica dos mesmos | |
| BR112018013408A2 (pt) | derivados de c-glicosídeo que têm anel fenila fusionado ou sais farmaceuticamente aceitáveis dos mesmos, método para preparar os mesmos e composição farmacêutica compreendendo os mesmos | |
| WO2022116997A8 (en) | Fused heterocyclic derivatives and their use in the treatment of hbv infection | |
| BR112022010204A2 (pt) | Derivado do anel de piridina fusionado, método de preparação para o mesmo e uso farmacêutico do mesmo | |
| BR112021023216A2 (pt) | Derivados heterocíclicos fundidos como agentes antivirais | |
| BR112018003181A2 (pt) | composto, composição, e, método para tratar infecção por hiv | |
| BR112018002678A2 (pt) | composto, composição, e, método para tratar infecção por hiv | |
| BR112017015474A2 (pt) | inibidores de bace1 | |
| BR112018015247A2 (pt) | composto, processo para a preparação de um composto, composição farmacêutica | |
| ECSP21092791A (es) | Derivados heterocíclicos condensados | |
| BR112018000253A2 (pt) | composto, composição, e, método para tratar a infecção pelo hiv. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |